About the Authors
Division of Cardiovascular and Medical Sciences, Faculty of Medicine, University of Glasgow, Glasgow, Scotland
Robertson Centre for Biostatistics, University of Glasgow, Glasgow, Scotland
Section of Gerontology and Geriatrics, Leiden University Medical Centre, Leiden, The Netherlands
Department of Pharmacology and Therapeutics, Cork University Hospital, Wilton, Cork, Ireland
Departments of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands
SC received research funding and honoraria from Astra Zeneca, makers of rosuvastatin. JS is a consultant to Astra Zeneca, GlaxoSmithKline, MSD, and Pfizer, and is on the Speakers Bureau for Astra Zeneca and Pfizer.
ICMJE criteria for authorship read and met: NS HMM PW GJB BMB SMC AJMdC GL JWJ PWM MBM DJS RGJW JS IF CJP. Agree with the manuscript's results and conclusions: NS HMM PW GJB BMB SMC AJMdC GL JWJ PWM MBM DJS RGJW JS IF CJP. Designed the experiments/the study: NS PW GJB BMB JWJ RGJW JS IF CJP. Analyzed the data: GJB BMB SMC GL JWJ PWM MBM DJS RGJW JS IF CJP. Collected data/did experiments for the study: NS HMM PW BMB AJMdC PWM RGJW IF CJP. Enrolled patients: GJB BMB AJMdC JWJ MBM RGJW JS. Wrote the first draft of the paper: NS PW. Contributed to the writing of the paper: NS HMM PW GJB BMB AJMdC GL JWJ PWM DJS RGJW JS IF CJP. Chaired Endpoints Committee for the PROSPER study, on which this article is based: SMC. Assay of fibrinogen and critical revision of article: GL. Leading investigator on Dutch team involved in PROSPER and coordinator of Dutch biobank: JWJ. Reviewed all study ECGs and was a member of the end points committee: PM. Endpoints committee member and adjudication of all possible vascular endpoints during the study: DJS. Director for the PROSPER study data centre and responsible for data capture, querying, and quality: IF.